Targets › TNFSF4
3 programs from 3 companies in 59 trials: 20 Phase 2, 19 Phase 3, 13 Phase 1, 7 Phase 4; Immunology, Neurology, Gastroenterology; next expected readout Nov 2026.
Cytokine that binds to TNFRSF4. Co-stimulates T-cell proliferation and cytokine production. (UniProt, P23510)
Open in Phaseline: the race on TNFSF4, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Sanofi | H5 Flu IMP 1 Rho-associated protein kinase 2 inhibitor; Rho-associated protein kinase inhibitor | ROCK2, ROCK1, TNFSF4, CD38, IL4R | Phase 4 | RSV Immunization; Diabetes Mellitus, Type 1; Asthma; Dermatitis Atopic … | Dec 2026 |
| Scleroderma Research Foundation, Inc. | Amlitelimab Tumor necrosis factor ligand superfamily member 4 inhibitor | TNFSF4 | Phase 2 | Interstitial Lung Disease Due to Systemic Disease | Nov 2026 |
| Oxion Biologics | OX118 human monoclonal antibody targeting OX40 ligand (OX40L) | TNFSF4 | Phase 1 | Immune System | – |
Dermatitis Atopic (5) Colitis Ulcerative (4) Chronic Graft Versus Host Disease (3) Crohn's Disease (3) Plasma Cell Myeloma Refractory (3) Asthma (2) Hemophilia (2) Plasma Cell Myeloma (2) Ulcerative Colitis (2) Type 1 Diabetes Mellitus (2) Healthy Volunteers (2) RSV Immunization (1)
protein or peptide (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.